Sonoran Biosciences

About:

Sonoran Biosciences is an early stage pharmaceutical company that has developed SB Gel, the first viscous sustained release carrier.

Website: http://www.sonoranbiosciences.com

Description:

Sonoran Biosciences is a privately held early stage pharmaceutical company that has developed SB Gel, the first viscous sustained release carrier. SB Gel enables sustained release of a wide variety of pharmaceuticals to new sites in the body, including joints, device surfaces, and healing tissues. We develop new formulations using approved active ingredients, requiring reduced development cost and risk via the 505(b)(2) approval pathway while retaining the exclusivity of a typical pharmaceutical. Formulations based on SB Gel have potential in a number of indications including deep infection, pain management, and wound healing. Our first product, SB Gel with tobramycin, is being developed for treatment of prosthetic joint infection in a one-stage surgical approach.

Total Funding Amount:

$1.48M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Scottsdale, Arizona, United States

Founded Date:

2012-01-01

Contact Email:

info(AT)sonoranbiosciences.com

Founders:

Derek Overstreet

Number of Employees:

11-50

Last Funding Date:

2016-08-17

IPO Status:

Private

Industries:

© 2025 bioDAO.ai